# Plasma pharmacokinetics of the combination of potassium chloride extended-release tablets and potassium citrate granules in patients with cardiovascular emergencies

## TL;DR

This study examines how potassium levels in the blood change when two potassium supplements are combined in patients with cardiovascular emergencies, helping to guide safe dosing.

## Contribution

The study provides real-world pharmacokinetic data for combined potassium supplementation in cardiovascular emergency patients.

## Key findings

- Tmax values increased with higher doses, reaching 6.11 hours for three-dose administration.
- Plasma potassium levels rose by 0.31 ± 0.05 mmol/L per dose, with linear correlation between dose and AUClimit.
- A one-compartment model best fits the pharmacokinetic data, supporting safe potassium supplementation strategies.

## Abstract

To simulate plasma pharmacokinetics (PK) parameters of combining potassium citrate granules and potassium chloride extended-release tablets using real-world data, guiding optimal dosing and timing for cardiovascular emergency patients.

A retrospective study analyzed PK characteristics in patients receiving both drugs at Fuwai Yunnan Hospital from January 1 to March 31, 2024, using non-compartmental analysis (NCA).

Among 330 patients, the Tmax values for 1-dose, 2-dose, and 3-dose administrations were 4.65 h, 6.00 h, and 6.11 h. The half-life (t1/2) was 1.33 h, 13.53 h, and 6.11 h, respectively. Each dose elevated plasma potassium by 0.31 ± 0.05 mmol/L. The limited areas under the plasma curve (AUClimit) were 30.37 mmol-h/L, 106.89 mmol-h/L, 141.74 mmol-h/L. Co-administered dose and AUClimit were linearly related (R2 = 0.9554).

PK data fit a 1-compartment model, supporting safe, rational potassium supplementation in cardiovascular emergencies.